{"entity":{"id":"mb-105","kind":"drug","name":"MB-105","aka":["CD5.CAR/28zeta CAR T cells (Baylor phase 1, name used in NCT03081910)"],"tldr":"MB-105 is an experimental autologous CAR T-cell therapy from March Biosciences, in phase 2 trials for CD5-positive T-cell lymphoma and T-cell acute lymphoblastic leukaemia.","summary":"MB-105 (CD5.CAR/28zeta CAR T cells (Baylor phase 1, name used in NCT03081910)) is an autologous CAR T-cell therapy from March Biosciences, with Baylor College of Medicine as partner. Autologous T cells engineered to express a CD5-directed chimeric antigen receptor; the company says its CAR design resists the CAR T cells killing each other during manufacture without extra gene editing. Its furthest stage is phase 2, for CD5-positive T-cell lymphoma and T-cell acute lymphoblastic leukaemia. ClinicalTrials.gov registers it in 2 studies linked below. Registry NCT06534060 phase 2 recruiting; long-term follow-up NCT07340814 not yet recruiting. Whether it works in people has not been established unless a trial below reports it.","status":"phase-2","asOf":"2026-11-03","links":[{"label":"March Biosciences: march.bio","url":"https://march.bio/mb-105/"},{"label":"March Biosciences: march.bio","url":"https://march.bio/mb-105/"},{"label":"March Biosciences: march.bio","url":"https://march.bio/pipeline/"},{"label":"March Biosciences: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT06534060"},{"label":"ClinicalTrials.gov: trials of MB-105","url":"https://clinicaltrials.gov/search?intr=MB-105"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["march-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06534060","nct07340814"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"MB-105","modality":"Autologous CAR T-cell therapy","mechanism":"Autologous T cells engineered to express a CD5-directed chimeric antigen receptor; the company says its CAR design resists the CAR T cells killing each other during manufacture without extra gene editing.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/mb-105/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"company":[{"id":"march-biosciences","kind":"company","name":"March Biosciences","route":"/companies/march-biosciences/"}],"trial":[{"id":"nct07340814","kind":"trial","name":"A Long-term Follow-up Study of Patients Who Received MB-105","route":"/trials/nct07340814/"},{"id":"nct06534060","kind":"trial","name":"MB-105 in Patients With CD5 Positive T-cell Lymphoma","route":"/trials/nct06534060/"}]}}